[go: up one dir, main page]

CA2000479A1 - Vasopermeability-enhancing conjugates - Google Patents

Vasopermeability-enhancing conjugates

Info

Publication number
CA2000479A1
CA2000479A1 CA2000479A CA2000479A CA2000479A1 CA 2000479 A1 CA2000479 A1 CA 2000479A1 CA 2000479 A CA2000479 A CA 2000479A CA 2000479 A CA2000479 A CA 2000479A CA 2000479 A1 CA2000479 A1 CA 2000479A1
Authority
CA
Canada
Prior art keywords
species
vasoactive
disclosed
agent
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2000479A
Other languages
French (fr)
Other versions
CA2000479C (en
Inventor
Alan L. Epstein
M. Michael Glovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2000479A1 publication Critical patent/CA2000479A1/en
Application granted granted Critical
Publication of CA2000479C publication Critical patent/CA2000479C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Conjugates having a clinically useful delivery vehicle linked to a biologically active species which acts to increase vascular permeability and expand blood volume at or in proximity to the tumor site are disclosed. the vehicle-linked species may be, for example, a vasoactive agent, a substance that recruits or amplifies a vasoactive species, a drug, or a pharmaceutical compound. Suitable biological species comprises peptides, lipids, carbohydrates, or their derivatives. Chemical or recombinant DNA methods suitable for linking the species to the vehicles are indicated. A therapy is disclosed which comprises administering the vasoactive conjugate and delivering a diagnostic agent or a therapeutic agent at an optimal time thereafter, when tumor vasculature is maximally affected.
CA002000479A 1988-10-11 1989-10-11 Vasopermeability-enhancing conjugates Expired - Lifetime CA2000479C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25551388A 1988-10-11 1988-10-11
US255,513 1988-10-11

Publications (2)

Publication Number Publication Date
CA2000479A1 true CA2000479A1 (en) 1990-04-11
CA2000479C CA2000479C (en) 2000-06-20

Family

ID=22968671

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002000479A Expired - Lifetime CA2000479C (en) 1988-10-11 1989-10-11 Vasopermeability-enhancing conjugates

Country Status (1)

Country Link
CA (1) CA2000479C (en)

Also Published As

Publication number Publication date
CA2000479C (en) 2000-06-20

Similar Documents

Publication Publication Date Title
EP0438497A4 (en) Vasopermeability-enhancing conjugates
US5543389A (en) Covalent polar lipid-peptide conjugates for use in salves
EP0861667A3 (en) Particulate agents
EP2347770B1 (en) Process for producing an injectable pharmaceutical preparation
CA2064689A1 (en) Stabilized protein or peptide conjugates
DE69534676T2 (en) Oral administration of chemically modified proteins
Fiume et al. Drug targeting in antiviral chemotherapy: A chemically stable conjugate of 9-β-d-arabinofuranosyl-adenine 5'-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells
AU608264B2 (en) Delivery vehicles with amphiphile-associated active ingredient
EP0329184A3 (en) Antimers and antimeric conjugation
WO1999024074A3 (en) Novel conjugates of opioids and endogenous carriers
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
HK1044290A1 (en) X-ray guided drug delivery
CA2182228A1 (en) Codrugs as a method of controlled drug delivery
CA2184242A1 (en) Drug Targeting System, Method for Preparing Same and Its Use
CA2295177A1 (en) Drug targeting system, method of its preparation and its use
IL97411A (en) Pharmaceutical formulations comprising hapten-modified diagnostic or therapeutic agents
WO1992022332A3 (en) Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
CA2242768A1 (en) Activatable infusable dispersions and methods for using them for therapy and diagnostics
AU8514291A (en) Particulate agents
CA2000479A1 (en) Vasopermeability-enhancing conjugates
JPH08109142A (en) Platelet drug delivery system
CA2073554A1 (en) Water-soluble composition for sustained-release
JPH06293631A (en) Drug delivery system using keratin dydrolyzate as carrier
JPH04501705A (en) Use of fibrinolytic agents for combined treatment of tumors
NZ335081A (en) Conjugates containing a cytotoxic drug attached via a bond or linker to an oligopeptide comprising at least one cyclic amino acid having a hydrophilic group useful in the treatment of prostate cancer

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry